CN1259332C - C2,5′－二取代的和n6，c2,5′－三取代的腺苷衍生物及其不同用途 - Google Patents

C2,5′－二取代的和n6，c2,5′－三取代的腺苷衍生物及其不同用途 Download PDF

Info

Publication number
CN1259332C
CN1259332C CNB028072014A CN02807201A CN1259332C CN 1259332 C CN1259332 C CN 1259332C CN B028072014 A CNB028072014 A CN B028072014A CN 02807201 A CN02807201 A CN 02807201A CN 1259332 C CN1259332 C CN 1259332C
Authority
CN
China
Prior art keywords
compound
deoxy
composition
active ingredient
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028072014A
Other languages
English (en)
Chinese (zh)
Other versions
CN1537115A (zh
Inventor
E·范迪尔伯格
A·伊泽曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Can Fite Biopharma Ltd
Leiden University
Original Assignee
Can Fite Biopharma Ltd
Leiden University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd, Leiden University filed Critical Can Fite Biopharma Ltd
Publication of CN1537115A publication Critical patent/CN1537115A/zh
Application granted granted Critical
Publication of CN1259332C publication Critical patent/CN1259332C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CNB028072014A 2001-03-03 2002-03-03 C2,5′－二取代的和n6，c2,5′－三取代的腺苷衍生物及其不同用途 Expired - Fee Related CN1259332C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0105337A GB2372742A (en) 2001-03-03 2001-03-03 C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
GB0105337.0 2001-03-03

Publications (2)

Publication Number Publication Date
CN1537115A CN1537115A (zh) 2004-10-13
CN1259332C true CN1259332C (zh) 2006-06-14

Family

ID=9909952

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028072014A Expired - Fee Related CN1259332C (zh) 2001-03-03 2002-03-03 C2,5′－二取代的和n6，c2,5′－三取代的腺苷衍生物及其不同用途

Country Status (9)

Country Link
US (2) US7084127B2 (enExample)
EP (1) EP1368365A2 (enExample)
JP (2) JP4359676B2 (enExample)
KR (1) KR100585894B1 (enExample)
CN (1) CN1259332C (enExample)
AU (1) AU2002234851A1 (enExample)
CA (1) CA2439879C (enExample)
GB (1) GB2372742A (enExample)
WO (1) WO2002070532A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070739A1 (en) * 2002-02-19 2003-08-28 Cv Therapeutics, Inc. Partial and full agonists of a1 adenosine receptors
JP2005132767A (ja) * 2003-10-30 2005-05-26 Sumitomo Chemical Co Ltd プリン化合物の製造方法
DK1706414T3 (da) * 2003-12-22 2008-10-13 Hoffmann La Roche Fremgangsmåde til fluorcytidinderivater
US20050277615A1 (en) * 2004-05-17 2005-12-15 Can-Fite Biopharma Ltd. Pharmaceutical compositions having anti-inflammatory activity
PE20060272A1 (es) * 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
US20080070860A1 (en) * 2005-02-04 2008-03-20 Uti Limited Partnership Adenosine Analogs Useful as Anti-Bacterial and Anti Protozoan Agents
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2010014921A2 (en) * 2008-08-01 2010-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
AU2009231978C1 (en) * 2008-03-31 2014-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as A3 adenosine receptor- selective agonists
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
US9199102B2 (en) 2009-07-21 2015-12-01 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation
JP2013516495A (ja) 2010-01-11 2013-05-13 イノテック ファーマシューティカルズ コーポレイション 眼圧を低下させる組合せ、キット、および方法
JP2013523739A (ja) 2010-03-26 2013-06-17 イノテック ファーマシューティカルズ コーポレイション Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
SMT201700377T1 (it) 2012-01-26 2017-09-07 Inotek Pharmaceuticals Corp Polimorfi anidri di (2r,3s,4r,5r)-5-(6-(ciclopentilammino)-9h-purin-9-il)-3,4- diidrossitetraidrofuran-2-il)}metil nitrato e processi di sua preparazione
WO2014068589A2 (en) * 2012-10-29 2014-05-08 Biophore India Pharmaceuticals Pvt. Ltd. Novel process for the preparation of (1-{9-[(4s, 2r, 3r, 5r)-3, 4-dihydroxy-5-(hydroxymethyl) oxolan-2-yl)-6-aminopurin-2-yl} pyrazole-4-yl)-n-methylcarboxamide
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
CN109076162B (zh) * 2016-04-22 2020-09-22 兴和株式会社 具备复用器的拍摄装置

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357324A (en) * 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
US5189027A (en) * 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
US5278150A (en) * 1992-04-24 1994-01-11 Whitby Research, Inc. 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1997033591A1 (en) 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
GB9610031D0 (en) 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
US5998423A (en) * 1996-10-08 1999-12-07 Therasys, Inc. Methods for modulating melanin production
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
ES2264826T3 (es) 1998-10-16 2007-01-16 Pfizer Inc. Derivados de adenina.
WO2000072799A2 (en) * 1999-05-27 2000-12-07 The University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
AU4138601A (en) * 1999-12-03 2001-06-12 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias

Also Published As

Publication number Publication date
CN1537115A (zh) 2004-10-13
GB0105337D0 (en) 2001-04-18
JP4359676B2 (ja) 2009-11-04
KR100585894B1 (ko) 2006-06-07
KR20030089512A (ko) 2003-11-21
GB2372742A (en) 2002-09-04
US7189706B2 (en) 2007-03-13
US20040132686A1 (en) 2004-07-08
US7084127B2 (en) 2006-08-01
US20040127452A1 (en) 2004-07-01
WO2002070532A2 (en) 2002-09-12
CA2439879C (en) 2009-09-15
CA2439879A1 (en) 2002-09-12
WO2002070532A3 (en) 2002-11-28
EP1368365A2 (en) 2003-12-10
JP2009167170A (ja) 2009-07-30
JP2004522794A (ja) 2004-07-29
AU2002234851A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
CN1537115A (zh) C2,5′－二取代的和n6,c2,5′－三取代的腺苷衍生物及其不同用途
CN100349913C (zh) 2′－氟代核苷
CN100343268C (zh) β－2′－或3′－卤代核苷
CN1516590A (zh) 4′-取代的核苷
CN1179970C (zh) 嘌呤衍生物
CN88102038A (zh) 脱氮杂嘌呤核苷衍生物及其制备方法药物组合物、用于核酸顺序和用作抗病毒剂
CN1268140A (zh) 单环l－核苷、类似物及其应用
Ma et al. Synthesis and anti-hepatitis B virus activity of 9-(2-deoxy-2-fluoro-β-l-arabinofuranosyl) purine nucleosides
CN1466591A (zh) 核苷衍生物
CN1434830A (zh) 2－氨基羰基－9h－嘌呤衍生物
CN1863813A (zh) 作为治疗剂的新型三环核苷或核苷酸
CN1653077A (zh) 治疗c型肝炎病毒感染的核苷衍生物
CN1423654A (zh) 2′－脱氧－l－核苷的合成
CN1265665A (zh) 苯并咪唑衍生物
CN1518450A (zh) 腺苷类似物用于制备治疗胰岛素抵抗综合征和糖尿病药物的用途
CN1571792A (zh) 2＇－卤代－β－L－阿拉伯呋喃糖基核苷的制备方法
CN1842535A (zh) β－L－2＇ －脱氧核苷的合成
CN1036578A (zh) 氟膦酸酯核苷酸衍生物
CN1744903A (zh) 2′－支链核苷的制备方法
HK1076473B (en) β-2'-OR 3'-HALONUCLEOSIDES
HK1072382A (en) B-l-2'-deoxy-nucleosides for the treatment of hepatitis b
CN1810822A (zh) 2－氨基羰基－9h－嘌呤衍生物
HK1029998A (en) Monocyclic l-nucleosides, analogs and uses thereof
CN1863538A (zh) 用于治疗c型肝炎病毒感染的核苷衍生物
HK1081556A (en) Nucleoside derivatives for treating hepatitis c virus infection

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060614

Termination date: 20100303